Ductal carcinoma in situ, or DCIS, accounts for up to 25% of diagnosed breast cancers and affects more than 50,000 women each year, according to the American Cancer Society. Often called “sta ...

In recent years, many researchers have been focused on DCIS: ductal carcinoma in situ, the earliest stage of cancer that in most cases remains in the milk ducts and does not invade other tissues.

According to two new studies presented Thursday at the San Antonio Breast Cancer Symposium, active monitoring of ductal carcinoma in situ (DCIS) resulted in breast cancer recurrence rates similar ...

A newly released study is challenging the way doctors commonly treat patients with ductal carcinoma in situ (DCIS), known as stage zero breast cancer. DCIS cancer cells are confined inside a milk ...

Women who took tamoxifen after undergoing a lumpectomy to remove ductal carcinoma in situ (DCIS) were 44% to 51% less likely to have their cancer return in that breast, researchers reported last week ...

“All current treatments for DCIS aim to reduce the risk of future invasive cancer, despite a growing body of evidence that not all DCIS is destined to progress,” said Dr. Shelley Hwang, a professor of ...

Opens in a new tab or window SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended ...

Another in the Journal of the American Medical Association suggests a new approach to a type of breast cancer called ductal carcinoma in situ, or DCIS. The research was discussed Thursday at the San ...

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront ...

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their ...

SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the ...

Women who took tamoxifen after undergoing a lumpectomy to remove ductal carcinoma in situ (DCIS) were 44% to 51% less likely to have their cancer return in that breast, researchers reported last ...